CLINICAL TRIALS PROFILE FOR DANICOPAN
✉ Email this page to a colleague
All Clinical Trials for danicopan
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT03053102 ↗ | Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) | Completed | Achillion, a wholly owned subsidiary of Alexion | Phase 2 | 2017-03-31 | The purpose of this study was to determine the safety and efficacy of ACH-0144471 (also known as danicopan and ALXN2040) in currently untreated participants with PNH. |
NCT03053102 ↗ | Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) | Completed | Achillion Pharmaceuticals | Phase 2 | 2017-03-31 | The purpose of this study was to determine the safety and efficacy of ACH-0144471 (also known as danicopan and ALXN2040) in currently untreated participants with PNH. |
NCT03053102 ↗ | Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) | Completed | Alexion Pharmaceuticals | Phase 2 | 2017-03-31 | The purpose of this study was to determine the safety and efficacy of ACH-0144471 (also known as danicopan and ALXN2040) in currently untreated participants with PNH. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for danicopan
Condition Name
Clinical Trial Locations for danicopan
Trials by Country
Clinical Trial Progress for danicopan
Clinical Trial Phase
Clinical Trial Sponsors for danicopan
Sponsor Name